etavopivat   Click here for help

GtoPdb Ligand ID: 11975

Synonyms: FT-4202 | FT4202
Compound class: Synthetic organic
Comment: Etavopivat (FT-4202) is an orally active, small molecule allosteric activator of the pyruvate kinase (PK) isoform that's found in erythrocytes (PK-R) [2]. It activates the erythrocytic glycolytic pathway. Etavopivat is similar in function to mitapivat.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 117.65
Molecular weight 457.13
XLogP -0.58
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC[C@@H](C(=O)N1CC2=C(C1)CN(C2)S(=O)(=O)c1cnc2c(c1)OCCO2)c1ccccc1
Isomeric SMILES C1COc2c(O1)cc(cn2)S(=O)(=O)N1CC2=C(C1)CN(C2)C(=O)[C@H](CO)c1ccccc1
InChI InChI=1S/C22H23N3O6S/c26-14-19(15-4-2-1-3-5-15)22(27)24-10-16-12-25(13-17(16)11-24)32(28,29)18-8-20-21(23-9-18)31-7-6-30-20/h1-5,8-9,19,26H,6-7,10-14H2/t19-/m1/s1
InChI Key KZFFYEPYCVDOGE-LJQANCHMSA-N
No information available.
Summary of Clinical Use Click here for help
Etavopivat (FT-4202) is being evaluated as a treatment for sickle cell disease. This modality offers potential clinical benefit for other genetic pyruvate kinase deficiencies and hemoglobinopathies. Phase 1 safety, pharmacokinetics, and pharmacodynamics data for etavopivat in healthy participants were published in Jan 2022 [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03815695 A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients Phase 1 Interventional Forma Therapeutics, Inc. 1
NCT04987489 A Study of FT-4202 in Patients With Thalassemia or Sickle Cell Disease Phase 2 Interventional Forma Therapeutics, Inc.